STAAR Surgical Co stock (US8577001096): Q1 net sales surge 119.6% to $93.5M

STAAR Surgical Co reported robust Q1 2026 results for the quarter ended April 3, 2026, with net sales jumping 119.6% year-over-year to $93.5 million, driven by China sales of $47.4 million and U.S. growth, according to StockTitan as of May 2026. The company swung from a $54.2 million net loss to $5.2 million net income, or $0.10 per diluted share, with gross margin expanding to 73.6% from 65.8%. Adjusted EBITDA turned positive at $24.4 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

STAAR Surgical Co: core business model

STAAR Surgical Co designs, develops, manufactures, and sells implantable lenses for the eye, primarily Implantable Collamer Lenses (ICLs), and delivery systems, according to its 10-Q filing as of May 2026. The company focuses on vision correction products for refractive errors, targeting markets seeking alternatives to laser surgery. Global ICL sales surpassed 4 million units, a key milestone highlighted in the Q1 earnings call.

Operations span manufacturing in Switzerland and the U.S., with recent scaling of the Swiss facility to serve China tariff-free. This supports growth in high-demand regions, enhancing competitiveness for U.S. investors tracking medtech exposure to Asia.

Main revenue and product drivers for STAAR Surgical Co

Net sales reached $93.5 million in Q1 2026 (ended April 3), up 119.6% from the prior year, with China contributing $47.4 million on EVO+ ICL launch success, per Benzinga transcript as of May 2026. U.S. sales also grew, bolstering results amid inventory normalization. Gross margin hit 73.6%, reflecting cost efficiencies and higher volumes.

ICLs remain the core driver, with EVO plus ICL gaining traction in China. Distributor sales and direct markets fuel revenue, relevant for U.S. investors as STAAR's Nasdaq listing (STAA) offers exposure to expanding elective vision procedures.

Industry trends and competitive position

The vision correction market grows with rising myopia rates in Asia, where STAAR holds strong positioning via ICLs as a reversible alternative to LASIK. China demand durability is key, as noted in pre-earnings analysis with revenue estimates up 16.85% over two months, according to Investing.com as of May 2026.

Why STAAR Surgical Co matters for US investors

Listed on Nasdaq as STAA, STAAR provides U.S. investors direct access to medtech growth in China and domestic markets. Q1 profitability turnaround and $163.9 million cash position underscore resilience, with U.S. sales contributing to diversified revenue amid global expansion.

Conclusion

STAAR Surgical Co's Q1 2026 results highlight sales momentum from China and product launches, with profitability recovery signaling operational improvements. Cash remains solid at $163.9 million despite cash flow pressures. Investors monitor China demand sustainability and manufacturing scale-up for ongoing performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.